vs
Apellis Pharmaceuticals, Inc.（APLS）与COUSINS PROPERTIES INC（CUZ）财务数据对比。点击上方公司名可切换其他公司
COUSINS PROPERTIES INC的季度营收约是Apellis Pharmaceuticals, Inc.的1.3倍（$255.0M vs $199.9M），COUSINS PROPERTIES INC净利率更高（-1.4% vs -29.5%，领先28.1%），COUSINS PROPERTIES INC同比增速更快（13.2% vs -5.9%），COUSINS PROPERTIES INC自由现金流更多（$135.0M vs $-14.3M），过去两年COUSINS PROPERTIES INC的营收复合增速更高（10.4% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Cousins Properties是一家公开上市的房地产投资信托（REIT），专注于亚特兰大、夏洛特、奥斯汀、菲尼克斯、坦帕及北卡罗来纳州教堂山的写字楼资产投资。公司曾开发多个知名地标项目，包括亚特兰大的CNN中心、奥姆尼体育馆、桃树中心191号大厦以及埃默里角商业综合体。
APLS vs CUZ — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $255.0M |
| 净利润 | $-59.0M | $-3.5M |
| 毛利率 | — | 67.4% |
| 营业利润率 | -25.6% | 67.5% |
| 净利率 | -29.5% | -1.4% |
| 营收同比 | -5.9% | 13.2% |
| 净利润同比 | -62.2% | -125.4% |
| 每股收益（稀释后） | $-0.40 | $-0.02 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $199.9M | $255.0M | ||
| Q3 25 | $458.6M | $248.3M | ||
| Q2 25 | $178.5M | $240.1M | ||
| Q1 25 | $166.8M | $250.3M | ||
| Q4 24 | $212.5M | $225.3M | ||
| Q3 24 | $196.8M | $209.2M | ||
| Q2 24 | $199.7M | $213.0M | ||
| Q1 24 | $172.3M | $209.2M |
| Q4 25 | $-59.0M | $-3.5M | ||
| Q3 25 | $215.7M | $8.6M | ||
| Q2 25 | $-42.2M | $14.5M | ||
| Q1 25 | $-92.2M | $20.9M | ||
| Q4 24 | $-36.4M | $13.6M | ||
| Q3 24 | $-57.4M | $11.2M | ||
| Q2 24 | $-37.7M | $7.8M | ||
| Q1 24 | $-66.4M | $13.3M |
| Q4 25 | — | 67.4% | ||
| Q3 25 | — | 67.8% | ||
| Q2 25 | — | 69.1% | ||
| Q1 25 | — | 69.2% | ||
| Q4 24 | — | 67.6% | ||
| Q3 24 | — | 68.5% | ||
| Q2 24 | — | 66.8% | ||
| Q1 24 | — | 66.0% |
| Q4 25 | -25.6% | 67.5% | ||
| Q3 25 | 48.7% | 68.1% | ||
| Q2 25 | -18.6% | 69.4% | ||
| Q1 25 | -50.0% | 66.0% | ||
| Q4 24 | -12.3% | 65.8% | ||
| Q3 24 | -24.0% | 67.9% | ||
| Q2 24 | -14.7% | 66.4% | ||
| Q1 24 | -36.0% | 66.3% |
| Q4 25 | -29.5% | -1.4% | ||
| Q3 25 | 47.0% | 3.5% | ||
| Q2 25 | -23.6% | 6.0% | ||
| Q1 25 | -55.3% | 8.3% | ||
| Q4 24 | -17.1% | 6.1% | ||
| Q3 24 | -29.2% | 5.4% | ||
| Q2 24 | -18.9% | 3.7% | ||
| Q1 24 | -38.5% | 6.4% |
| Q4 25 | $-0.40 | $-0.02 | ||
| Q3 25 | $1.67 | $0.05 | ||
| Q2 25 | $-0.33 | $0.09 | ||
| Q1 25 | $-0.74 | $0.12 | ||
| Q4 24 | $-0.30 | $0.09 | ||
| Q3 24 | $-0.46 | $0.07 | ||
| Q2 24 | $-0.30 | $0.05 | ||
| Q1 24 | $-0.54 | $0.09 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $5.7M |
| 总债务越低越好 | — | $3.3B |
| 股东权益账面价值 | $370.1M | $4.7B |
| 总资产 | $1.1B | $8.9B |
| 负债/权益比越低杠杆越低 | — | 0.71× |
8季度趋势，按日历期对齐
| Q4 25 | $466.2M | $5.7M | ||
| Q3 25 | $479.2M | $4.7M | ||
| Q2 25 | $370.0M | $416.8M | ||
| Q1 25 | $358.4M | $5.3M | ||
| Q4 24 | $411.3M | $7.3M | ||
| Q3 24 | $396.9M | $76.1M | ||
| Q2 24 | $360.1M | $6.0M | ||
| Q1 24 | $325.9M | $5.5M |
| Q4 25 | — | $3.3B | ||
| Q3 25 | — | $3.3B | ||
| Q2 25 | — | $3.5B | ||
| Q1 25 | — | $3.0B | ||
| Q4 24 | — | $3.1B | ||
| Q3 24 | — | $2.7B | ||
| Q2 24 | — | $2.6B | ||
| Q1 24 | $93.1M | $2.6B |
| Q4 25 | $370.1M | $4.7B | ||
| Q3 25 | $401.2M | $4.7B | ||
| Q2 25 | $156.3M | $4.8B | ||
| Q1 25 | $164.2M | $4.8B | ||
| Q4 24 | $228.5M | $4.8B | ||
| Q3 24 | $237.1M | $4.4B | ||
| Q2 24 | $264.3M | $4.5B | ||
| Q1 24 | $266.7M | $4.5B |
| Q4 25 | $1.1B | $8.9B | ||
| Q3 25 | $1.1B | $8.9B | ||
| Q2 25 | $821.4M | $9.1B | ||
| Q1 25 | $807.3M | $8.7B | ||
| Q4 24 | $885.1M | $8.8B | ||
| Q3 24 | $901.9M | $7.8B | ||
| Q2 24 | $904.5M | $7.7B | ||
| Q1 24 | $831.9M | $7.7B |
| Q4 25 | — | 0.71× | ||
| Q3 25 | — | 0.70× | ||
| Q2 25 | — | 0.73× | ||
| Q1 25 | — | 0.63× | ||
| Q4 24 | — | 0.64× | ||
| Q3 24 | — | 0.60× | ||
| Q2 24 | — | 0.58× | ||
| Q1 24 | 0.35× | 0.57× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $402.3M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $135.0M |
| 自由现金流率自由现金流/营收 | -7.1% | 53.0% |
| 资本支出强度资本支出/营收 | 0.1% | 104.8% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
| Q4 25 | $-14.2M | $402.3M | ||
| Q3 25 | $108.5M | $120.5M | ||
| Q2 25 | $4.4M | $122.6M | ||
| Q1 25 | $-53.4M | $44.8M | ||
| Q4 24 | $19.4M | $400.2M | ||
| Q3 24 | $34.1M | $117.4M | ||
| Q2 24 | $-8.3M | $125.5M | ||
| Q1 24 | $-133.0M | $28.3M |
| Q4 25 | $-14.3M | $135.0M | ||
| Q3 25 | $108.3M | — | ||
| Q2 25 | $4.4M | — | ||
| Q1 25 | $-53.4M | — | ||
| Q4 24 | $19.3M | $147.5M | ||
| Q3 24 | — | — | ||
| Q2 24 | $-8.4M | — | ||
| Q1 24 | $-133.3M | — |
| Q4 25 | -7.1% | 53.0% | ||
| Q3 25 | 23.6% | — | ||
| Q2 25 | 2.5% | — | ||
| Q1 25 | -32.0% | — | ||
| Q4 24 | 9.1% | 65.5% | ||
| Q3 24 | — | — | ||
| Q2 24 | -4.2% | — | ||
| Q1 24 | -77.3% | — |
| Q4 25 | 0.1% | 104.8% | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | 112.2% | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.2% | — |
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | 14.03× | ||
| Q2 25 | — | 8.46× | ||
| Q1 25 | — | 2.14× | ||
| Q4 24 | — | 29.35× | ||
| Q3 24 | — | 10.48× | ||
| Q2 24 | — | 16.01× | ||
| Q1 24 | — | 2.13× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
CUZ
| Rental Properties | $253.3M | 99% |
| Fee And Other Revenue | $1.7M | 1% |
| Other | $1.2M | 0% |
